Tag: agonist

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Pfizer Inc., Merck & Co. Inc., Zealand Pharma A/S, Hanmi Pharmaceutical Co. Ltd. and others.

EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026

MELBOURNE, Australia, June 15, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications, notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies.

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --